Analysis of China’s peptide drug market scale and industry development trend in 2021

Polypeptide drugs have a large molecular weight and a short half-life.

They are easily decomposed by enzymes in the body and are difficult to absorb through the digestive system. Therefore, they are usually administered by injection.

The quality control level of peptide drugs is close to small molecule chemical drugs, and the activity is close to protein drugs. Combining the advantages of the two, it shows its own superiority in clinical application and production and preparation, with high activity, low dose, and low dose. The advantages of toxicity, etc., are suitable for solving complex diseases that are difficult to solve by small molecule chemical drugs.

　　Industry market size

　　 Although China’s peptide drug market started late, it has developed rapidly. Sales rose from 24.19 billion yuan in 2016 to 35.78 billion yuan in 2020, with a growth rate of over 15% during the period.

It is estimated that the sales of peptide drugs in China will reach 38.71 billion yuan in 2021. With the introduction of China’s policies to encourage the research and development of innovative drugs and promote the consistency evaluation of generic drugs, it is expected that more innovative peptide drugs and peptide generic drugs with significant clinical effects will be approved for marketing in the future, which will further expand the Chinese peptide drug market.

　　Data source: Compiled by China Commercial Industry Research Institute

　　Industry prospect analysis

　　 On the whole, China’s peptide drug market is still in the development stage. For a period of time in the future, China’s peptide drug industry will still be dominated by generic drugs, and innovation will mainly focus on the research and development of peptide generic drugs and the improvement and optimization of production processes. However, the gap also means room for improvement. China’s peptide drug industry is currently facing huge development opportunities, which are mainly reflected in:

　　1) Policies strongly support the promotion of industry development

　　 In order to enhance the core competitiveness of China’s pharmaceutical industry and promote the sustainable and healthy development of the industry, the State Council, the State Food and Drug Administration and other departments have continuously introduced new policies to support the development of the pharmaceutical industry to further promote the development of the industry.

The State Council issued a national-level strategic plan for the healthy development of the pharmaceutical industry, and issued the “Guiding Opinions on Promoting the Healthy Development of the Pharmaceutical Industry”, which made guiding arrangements for the pharmaceutical industry’s strategic position, current situation and future development plans in the development of the national economy;

In the future tasks, it is pointed out that “accelerating the development and industrialization of new antibodies, proteins and peptides and other biological drugs” has pointed out the direction for the development of the peptide industry. At the same time, as the country deepens the reform of the drug review and approval system, the approval of products with clear clinical efficacy that are not on the market in foreign markets will be accelerated.

　　 At the same time, with the continuous deepening of the new medical reform, the burden of basic medical and health expenses on the residents will be effectively alleviated, which will greatly promote medical and health consumption in the future.

　　2) The localization of peptide drugs stimulates the development of the industry

　　 At present, the domestic peptide drug market is dominated by imported drugs, and expensive prices have become an important factor in inhibiting the release of peptide drugs. 2014-2022 is the peak period for patent expiration of blockbuster varieties of peptide drugs.

Many varieties have not yet been marketed in China or only imported original research drugs have been marketed. Among them, there are many glatiramer and liraru with global sales of more than 1 billion US dollars. Peptides, exenatide, goserelin, etc.

Although Chinese pharmaceutical companies still have a certain gap with international giants in terms of innovative peptide drugs, in terms of peptide generic drugs, some domestic professional peptide drug manufacturers have reached a higher level, and have successively achieved bivarrudine and cannibalism.

The localization of Rick, Cetrorelix, Enfuvirtide, Carbetocin, Atosiban Acetate, Etibatide and other varieties shows the R&D strength of local enterprises in the field of peptides. Therefore, the lack of localization of more patent expired drugs has made China’s peptide generic drugs field great potential and broad industry development.

　　3) Increased acceptance of peptide drugs and expanded market demand

　　Peptide drugs are currently mainly administered through small-volume injections, with small dosages and easy clinical application. At the same time, since polypeptides are human body-derived components, they have the characteristics of good curative effect and low side effects.

In recent years, with the continuous development of the peptide drug industry and the continuous expansion of the scope of clinical application, doctors’ acceptance of peptide drugs has increased, which has further promoted the development of peptide drugs.

At present, peptide drugs have been widely used in multiple therapeutic fields such as anti-tumor, immune system, digestive system, diabetes, orthopedics, obstetrics and so on. In the future, the amount of drugs used in the market will further increase, the industry demand will greatly increase, and the scale will be expanded.

For more information, please refer to the “Research Report on China’s Peptide Drug Market Prospects and Investment Opportunities” issued by the China Commercial Industry Research Institute. At the same time, China Commercial Industry Research Institute also provides industrial big data, industrial intelligence, industrial research reports, industrial planning, and park planning. , Fourteenth Five-Year Plan, industry investment and other services.